Synopsis
Laurus Labs has been a strong player in active pharmaceutical ingredients for antiretrovirals. It has now gone ahead and built a sizeable finished-products business. But given that growth in antiretrovirals could plateau soon and scaling up in markets like the US is a challenge, there will be questions over maintaining the momentum in the formulations business.
In December 2016, a relatively young company from Hyderabad, making active pharmaceutical ingredients (APIs) mostly for HIV drugs, made a decent debut on the stock exchanges at a 14% premium on its issue price. Today, it is a chartbuster. Laurus Labs has come into the limelight, with its share price and earnings hitting new highs. There is increasing interest among investors in this company, which posted a whopping 1,047% growth in net profit
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Sign in to read the full article
You’ve got this Prime Story as a Free Gift
Yearly
(Save 49%)
₹2499
15
Days Trial
+Includes DocuBay and TimesPrime Membership worth ₹1499 & ₹999 resp.
2-Year
(Save 63%)
₹3599
15
Days Trial
+Includes DocuBay and TimesPrime Membership worth ₹1499 & ₹999 resp.
Already a Member? Sign In now
Why ?
Sharp Insight-rich, Indepth stories across 20+ sectors
-
Access the exclusive Economic Times stories, Editorial and Expert opinion
-
Clean experience with
Minimal Ads -
Comment & Engage with ET Prime community -
Exclusive invites to Virtual Events with Industry Leaders -
A trusted team of Journalists & Analysts who can best filter signal from noise
